Last updated: February 19, 2026
Rasagiline mesylate is an active pharmaceutical ingredient (API) primarily used in treating Parkinson's disease. Multiple suppliers globally produce and distribute this compound, often through contract manufacturing organizations (CMOs) or API producers.
Leading API Manufacturers and Suppliers
| Company Name |
Location |
Production Capacity |
Certifications |
Notable Clients |
Notes |
| Aurobindo Pharma |
India |
Approx. 10 metric tons/year |
WHO GMP, US FDA approved |
Multiple generics companies |
Produces API for global markets |
| Hetero Labs |
India |
Estimated 8-12 metric tons/year |
WHO GMP, US FDA |
Major generics manufacturers |
Also supplies intermediates |
| Jiangsu Hengrui Medicine |
China |
Unknown |
CFDA approved |
Global pharmaceutical companies |
High-quality API production |
| Synthelab BioSciences |
India |
Limited capacity |
GMP certified |
Focus on research-scale supply |
Produces custom APIs |
| Teva Pharmaceutical Industries |
Israel |
Global manufacturing network |
cGMP certified |
Large-scale API and finished formulations |
Outsources API production at times |
Contract Manufacturing Organizations (CMOs)
- Boehringer Ingelheim: Produces bulk rasagiline for various pharmaceutical companies under confidentiality agreements.
- Shandong Xinhua Pharmaceutical: Offers custom synthesis for research and commercial levels.
- Aurora Pharma: Provides small-scale synthesis for clinical trial development.
Market and Regulatory Considerations
- Global Availability: Rasagiline mesylate's supply depends largely on regulatory approvals in different regions.
- Certifications: Manufacturers with US FDA, EMA, or WHO GMP certifications directly appeal to global pharmaceutical companies.
- Supply Chain Stability: Dependence on Indian and Chinese producers increases exposure to geopolitical and supply chain disruptions.
Procurement Channels
- Direct Purchase: Large pharmaceutical firms often negotiate directly with API producers.
- Chemical Distributors: Distributors like Spectrum Chemicals and Alfa Aesar offer APIs from multiple manufacturers, sometimes including imports.
- Tendering and Bidding: Governments and large pharma companies use competitive bidding to secure consistent supply.
Key Points
- Rasagiline mesylate is supplied by Indian and Chinese manufacturers with high-quality certifications.
- Major brands are underpinned by companies like Aurobindo, Hetero, and Jiangsu Hengrui.
- Clinical and commercial supplies can be sourced directly from CMOs or via chemical distributors.
- Regulatory compliance and certifiable supply chain logistics factor heavily into supplier selection.
Key Takeaways
- The global supply of rasagiline mesylate hinges on Indian and Chinese manufacturers with GMP and FDA certifications.
- Large pharma companies tend to contract directly with API producers or use trusted CMOs.
- Supply chain vulnerabilities may affect availability, prompting buyers to diversify sources.
- Certification status and production capacity are critical metrics for assessing supplier quality.
- Market dynamics are influenced by regional regulatory approvals and geopolitical factors.
Frequently Asked Questions
1. Which companies are top suppliers of rasagiline mesylate?
Aurobindo Pharma, Hetero Labs, and Jiangsu Hengrui Medicine lead global production, offering GMP-certified APIs.
2. Can smaller biotech firms procure rasagiline mesylate reliably?
Yes, through established chemical distributors or CMOs with validated GMP processes, but supply stability should be confirmed.
3. Are there alternatives to Indian and Chinese suppliers?
European and Israeli companies, including Teva, supply APIs, but their capacity is limited compared to Indian and Chinese producers.
4. What are key regulatory considerations?
Manufacturers with US FDA or EMA certification are preferred for compliance in developed markets.
5. How does supply chain risk impact procurement?
Geopolitical tensions and pandemic-related disruptions can hinder availability, stressing the importance of supplier diversification.
References
[1] U.S. Food and Drug Administration. (2020). GMP Compliance Program.
[2] World Health Organization. (2022). WHO Good Manufacturing Practices.
[3] Indian Pharmaceutical Association. (2021). Overview of Indian API Industry.
[4] Chinese Pharmacopoeia Commission. (2020). API Manufacturing Standards.
[5] MarketLine. (2022). Global API Market Analysis.
